Related Experiment Video
Updated: Aug 9, 2026
09:21
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
[Paratesticular rhabdomyosarcoma]
Urologiia (Moscow, Russia : 1999)
|June 19, 2003
Summary
Paratesticular rhabdomyosarcoma (PR) is a common tumor in men, often spreading to retroperitoneal lymph nodes. Treatment involves surgery, lymphadenectomy, and adjuvant therapies, with prognosis depending on disease stage and age.
Area of Science:
- Oncology
- Urology
Context:
- Paratesticular rhabdomyosarcoma (PR) is the most common paratesticular tumor.
- It primarily affects young and middle-aged men.
- Early metastasis to retroperitoneal lymph nodes is characteristic.
Purpose:
- To outline the diagnostic and treatment strategies for paratesticular rhabdomyosarcoma.
- To discuss the role of surgery, lymphadenectomy, and adjuvant therapies.
- To highlight factors influencing the prognosis of PR.
Summary:
- Orchofuniculectomy is the primary treatment for PR.
- Metastases-free patients receive preventive retroperitoneal lymphadenectomy and adjuvant chemoradiotherapy.
- Disseminated PR requires combined treatment, including surgical removal of foci and adjuvant chemo- or chemoradiotherapy. Chemotherapy is used if complete surgical removal is not possible.
- Radiation therapy for metastatic retroperitoneal lymph nodes is ineffective.
Impact:
- Provides a comprehensive overview of PR management.
- Emphasizes the importance of multimodal treatment approaches.
- Informs prognosis based on age, stage, and treatment effectiveness.
